Ionetix

Ionetix Corporation is a leading innovator in cyclotron technology and isotope manufacturing, specializing in the production and distribution of radiopharmaceuticals for both diagnostic and therapeutic applications. The company's core technology is its proprietary cyclotron platform, which allows for the efficient production of scarce radioisotopes used in a variety of medical imaging and treatment procedures. Ionetix's commitment to innovation is demonstrated by its recent development of a commercial-scale production solution for Actinium-225, an alpha-emitter used in Targeted Alpha Therapy (TAT), a promising new approach for cancer treatment.

Ionetix offers a range of services to its customers, including turnkey diagnostic radiopharmaceutical services, cyclotron equipment and installation, and development of TAT isotope production and pharmaceutical manufacturing. The company operates a state-of-the-art isotope production facility in Lansing, Michigan, which is dedicated to the production of alpha-emitting isotopes, and is committed to expanding its global reach to meet the growing demand for its products and services.

Ionetix does not mention anything about job flexibility on their website or job postings. NONE

Ionetix is a leading innovator in cyclotron technology and isotope manufacturing, dedicated to providing cutting-edge diagnostics and therapeutics. Their mission is to partner with researchers, drug developers, and healthcare providers to deliver access to scarce radiopharmaceuticals that improve patient care. They strive to address the critical need for reliable and scalable production of isotopes for both diagnostic and therapeutic applications, particularly in the growing field of targeted alpha therapy. Ionetix is committed to advancing healthcare by delivering innovative solutions that enable the development and accessibility of life-changing treatments.

Ionetix promotes a culture of innovation, collaboration, and a commitment to providing cutting-edge diagnostics and therapeutics. This is reflected in their focus on developing and supplying scarce radiopharmaceuticals, their dedication to research and development, and their commitment to building a robust supply chain to meet the growing needs of the medical community.